Scholarlink

Background <p>Tissue factor (TF), a key initiator of the coagulation cascade, is frequently overexpressed in pancreatic cancer and linked to tumor progression and thrombosis. While TF has been recognized as a prognostic biomarker, its clinical relevance in surgically treated patients remains unclear.</p> Methods <p>We retrospectively analyzed TF expression in resected pancreatic cancer specimens from 265 patients, including those with and without preoperative therapy, using immunohistochemistry. Tissue factor expression was semiquantitatively classified as negative, low, or high. Associations with clinicopathological features, treatment response, and survival were evaluated.</p> Results <p>High TF expression was observed in 17.4% of cases and was significantly associated with elevated CA19-9, biologically borderline resectable disease, and lymph node metastases. These patients had shorter overall survival (median overall survival: 20.6 vs. 38.8 vs. 53.6 months, <i>p </i>&lt; 0.001). High TF expression remained an independent predictor of poor prognosis (hazard ratio [HR]: 2.21, <i>p </i>= 0.0002). Tissue factor-negative tumors were associated with favorable outcomes, including long-term survival despite recurrence. Tissue factor expression decreased following preoperative therapy but did not correlate with histological response.</p> Conclusions <p>Tissue factor expression stratifies pancreatic cancer into biologically and prognostically distinct subgroups. While high TF expression indicates aggressive disease and poor survival, TF-negative tumors represent an indolent, treatment-sensitive subtype. These findings underscore the biological heterogeneity of pancreatic cancer and support TF as a clinically relevant prognostic biomarker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer

  • 期刊论文

  • 发表日期：

    2026年3月12日

查看全文
  • Mariko Kamiya,
  • Shiro Koizume,
  • Tatsuya Kanai,
  • Rei Kanemoto,
  • Naohiko Matsushita,
  • Shinnosuke Kawahara,
  • Yuto Kamioka,
  • Masaaki Murakawa,
  • Kota Washimi,
  • Satoshi Kobayashi,
  • Toru Aoyama,
  • Makoto Ueno,
  • Naoto Yamamoto,
  • Takashi Oshima,
  • Soichiro Morinaga,
  • Aya Saito,
  • Yohei Miyagi

摘要

Background

Tissue factor (TF), a key initiator of the coagulation cascade, is frequently overexpressed in pancreatic cancer and linked to tumor progression and thrombosis. While TF has been recognized as a prognostic biomarker, its clinical relevance in surgically treated patients remains unclear.

Methods

We retrospectively analyzed TF expression in resected pancreatic cancer specimens from 265 patients, including those with and without preoperative therapy, using immunohistochemistry. Tissue factor expression was semiquantitatively classified as negative, low, or high. Associations with clinicopathological features, treatment response, and survival were evaluated.

Results

High TF expression was observed in 17.4% of cases and was significantly associated with elevated CA19-9, biologically borderline resectable disease, and lymph node metastases. These patients had shorter overall survival (median overall survival: 20.6 vs. 38.8 vs. 53.6 months, p < 0.001). High TF expression remained an independent predictor of poor prognosis (hazard ratio [HR]: 2.21, p = 0.0002). Tissue factor-negative tumors were associated with favorable outcomes, including long-term survival despite recurrence. Tissue factor expression decreased following preoperative therapy but did not correlate with histological response.

Conclusions

Tissue factor expression stratifies pancreatic cancer into biologically and prognostically distinct subgroups. While high TF expression indicates aggressive disease and poor survival, TF-negative tumors represent an indolent, treatment-sensitive subtype. These findings underscore the biological heterogeneity of pancreatic cancer and support TF as a clinically relevant prognostic biomarker.